112 related articles for article (PubMed ID: 38945936)
21. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.
Davtyan H; Hovakimyan A; Kiani Shabestari S; Antonyan T; Coburn MA; Zagorski K; Chailyan G; Petrushina I; Svystun O; Danhash E; Petrovsky N; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
Alzheimers Res Ther; 2019 Dec; 11(1):107. PubMed ID: 31847886
[TBL] [Abstract][Full Text] [Related]
22. Direct Interaction between the β-Amyloid Core and Tau Facilitates Cross-Seeding: A Novel Target for Therapeutic Intervention.
Tripathi T; Khan H
Biochemistry; 2020 Feb; 59(4):341-342. PubMed ID: 31944100
[TBL] [Abstract][Full Text] [Related]
23. Tau immunotherapies for Alzheimer's disease.
Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B
Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578
[TBL] [Abstract][Full Text] [Related]
24. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
Yadollahikhales G; Rojas JC
Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
[TBL] [Abstract][Full Text] [Related]
25. [Development of antibodies for immunotherapy of Alzheimer's disease].
Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
[TBL] [Abstract][Full Text] [Related]
26. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
[TBL] [Abstract][Full Text] [Related]
27. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
Wisniewski T; Boutajangout A
Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
[TBL] [Abstract][Full Text] [Related]
29. p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
Walls KC; Ager RR; Vasilevko V; Cheng D; Medeiros R; LaFerla FM
Neurosci Lett; 2014 Jul; 575():96-100. PubMed ID: 24887583
[TBL] [Abstract][Full Text] [Related]
30. Passive immunotherapy for Alzheimer's disease.
Guo X; Yan L; Zhang D; Zhao Y
Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
[TBL] [Abstract][Full Text] [Related]
31. Diverse molecular targets for therapeutic strategies in Alzheimer's disease.
Han SH; Mook-Jung I
J Korean Med Sci; 2014 Jul; 29(7):893-902. PubMed ID: 25045220
[TBL] [Abstract][Full Text] [Related]
32. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
Suzuki K; Iwata A; Iwatsubo T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
[TBL] [Abstract][Full Text] [Related]
33. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
[TBL] [Abstract][Full Text] [Related]
34. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
Golde TE
J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
[TBL] [Abstract][Full Text] [Related]
35. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
36. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
37. Tau-targeting therapies for Alzheimer disease.
Congdon EE; Sigurdsson EM
Nat Rev Neurol; 2018 Jul; 14(7):399-415. PubMed ID: 29895964
[TBL] [Abstract][Full Text] [Related]
38. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.
Karran E; De Strooper B
Nat Rev Drug Discov; 2022 Apr; 21(4):306-318. PubMed ID: 35177833
[TBL] [Abstract][Full Text] [Related]
39. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
[TBL] [Abstract][Full Text] [Related]
40. Antibody-based therapy in Alzheimer's disease.
Pul R; Dodel R; Stangel M
Expert Opin Biol Ther; 2011 Mar; 11(3):343-57. PubMed ID: 21261567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
